Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors

Journal of the National Cancer Institute

Volumn 107, Issue 9, 2015, Pages

  Chen, Tai Tsang ^a,b  

^a BRISTOL MYERS SQUIBB   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; IPILIMUMAB; ANTINEOPLASTIC AGENT;

CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG DEVELOPMENT; DRUG EFFICACY; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LONG TERM CARE; LONG TERM SURVIVAL; METASTATIC MELANOMA; MILESTONE SURVIVAL; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SAMPLE SIZE; BIOASSAY; CELL CYCLE CHECKPOINT; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; METHODOLOGY; MORTALITY; NEOPLASMS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; TRENDS;

ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84942240637     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv156     Document Type: Review

References (35)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
2. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimula-tory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95-106.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
5. Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacar-bazine in a phase III trial. J Clin Oncol. 2015;33(10):1191-1196.
6. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-2047.
7. Lebbé C, Weber JS, Maio M, et al. Survival follow-up and ipilimumab retreat-ment for patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol. 2014;25(11):2277-2284.
8. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015; In press.
9. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.
10. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34(6):585-612.
11. Cox DR. Regression Models and life-tables (with discussion). J Roy Statist Soc B. 1972;34(2):187-220.
12. Chen TT. Statistical issues and challenges in immuno-oncology. J Immunother Cancer. 2013;1:18.
13. Shea MB, Roberts SA, Walrath JC, Allen JD, Sigal EV. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals. Clin Cancer Res. 2013;19(14):1-10.
14. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
15. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
16. Weber JS, Minor DR, D'Angelo S P, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. Ann Oncol. 2014;25(Suppl 4):Abstr LBA3.
17. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambroli-zumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.
18. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
19. Herbst RS, Gordon MS, Fine GD, et al. A study of MPD3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors [abstract 3000]. J Clin Oncol. 2013;31(Suppl):15s.
20. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multi-centre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155-164.
21. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
22. Hoos A, Eggermont AMM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388-1397.
23. Berry DA. The hazards of endpoints. J Natl Cancer Inst. 2010;102(18):1376-1377.
24. Ribas A, Hersey P, Middleton MR, et al. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2011;18(2):336-341.
25. Conference on Clinical Cancer Research-Issue Brief. November 2013. Accessible at: http://www.pharmamedtechbi.com/~/media/Supporting%20 Documents/The%20Pink%20Sheet/75/46/FOCR-immunotherapy-issue- brief.pdf. (Accessed April 17, 2015)
26. Dolgin E. Cancer immunotherapy advances spawn calls for new endpoints. Nat Med. 2013;19(11):1357.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn. 1958;53(282):457-481.
28. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1(11):710-719.
29. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549-556.
30. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64(2):191-199.
31. Lan K, DeMets D. Discrete sequential boundaries for clinical trials. Biome-trika. 1983;70(3):659-663.
32. Haybittle JL. Repeated assessments of results in clinical trials of cancer treatment. Brit J Radiol. 1971; 44(526):793-797.
33. Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fxed point in time. Stat Med. 2007;26(24):4505-4519.
34. Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial effcacy and safety results from the EORTC 18071 phase III trial [abstract LBA9008]. J Clin Oncol. 2014;32(Suppl):5s.
35. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised double-blind phase 3 trial. Lancet Oncol. 2014;15(7):700-712.